$4.20
-4.76%Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Quality against peers; 50 is the peer median.
No reported financials for this company yet: it has too few SEC filings to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
From the notes to the annual report for fiscal 2025, ending December.
The next report, and the record against analysts' estimates.
Fundamentals: trailing twelve months to Sep 2026, from the latest 10-K and 10-Qs.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.